Is TRIL A Good Stock To Buy According To Hedge Funds?
Is TRIL A Good Stock To Buy According To Hedge Funds?
Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another high in recent weeks. On the other hand, technology hedge funds weren't timid and registered double digit market beating gains. Financials, energy and industrial stocks aren't doing great but many of the stocks that delivered strong returns since March are still going very strong and hedge funds actually increased their positions in these stocks. In this article we will find out how hedge fund sentiment to Trillium Therapeutics Inc. (NASDAQ:TRIL) changed recently.
包括沃倫·巴菲特(Warren Buffett)、大衞·泰珀(David Tepper)和斯坦·德魯肯米勒(Stan Druckenmiler)在內的許多知名投資者一直對當前的牛市持謹慎態度，並在最近幾周股市再創新高時錯失了良機。另一方面，科技對衝基金毫不畏懼，實現了兩位數的超越大盤的收益。金融、能源和工業類股表現不佳，但自3月份以來帶來強勁回報的許多股票仍然非常強勁，對衝基金實際上增加了這些股票的頭寸。在這篇文章中，我們將瞭解對衝基金情緒是如何延齡草治療公司(Trillium Treateutics Inc.)(納斯達克股票代碼：TRIL)最近發生了變化。
Is TRIL a good stock to buy?Trillium Therapeutics Inc. (NASDAQ:TRIL) shareholders have witnessed an increase in activity from the world's largest hedge funds lately. Trillium Therapeutics Inc. (NASDAQ:TRIL) was in 32 hedge funds' portfolios at the end of September. The all time high for this statistic is 25. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. Our calculations also showed that TRIL isn't among the 30 most popular stocks among hedge funds (click for Q3 rankings and see the video for a quick look at the top 5 stocks).Video: Watch our video about the top 5 most popular hedge fund stocks.
Tril是值得買的好股票嗎？延齡治療公司(納斯達克交易代碼：TRIL)的股東最近見證了世界上最大的對衝基金的活動增加。截至9月底，Trillium治療公司(納斯達克市場代碼：TRIL)在32家對衝基金的投資組合中。這一統計數據的歷史最高值是25。這意味着這隻股票的看漲對衝基金頭寸數量目前處於歷史最高水平。我們的計算還顯示，Tril不在對衝基金最受歡迎的30只股票之列(點擊查看第三季度排名，快速瀏覽前5只股票的視頻)。視頻：觀看我們關於最受歡迎的5只對衝基金股票的視頻。
In today’s marketplace there are a large number of tools investors put to use to evaluate their stock investments. A duo of the best tools are hedge fund and insider trading activity. Our experts have shown that, historically, those who follow the best picks of the best hedge fund managers can trounce the market by a healthy margin (see the details here).Richard Driehaus of Driehaus Capital
在今天的歐元™市場上，投資者可以使用大量的工具來評估他們的股票投資。對衝基金和內幕交易活動是兩個最好的工具。我們的專家已經證明，從歷史上看，那些遵循最好的對衝基金經理的人可以以健康的優勢擊敗市場(請看這裏的詳細信息)。Driehaus Capital的理查德·德里豪斯(Richard Driehaus)
At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, the House passed a landmark bill decriminalizing marijuana. So, we are checking out this under the radarcannabis stockright now. We go through lists like the 15best blue chip stocks to buyto pick the best large-cap stocks to buy. Even though we recommend positions in only a tiny fraction of the companies we analyze, we check out as many stocks as we can. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. You can subscribe to our free daily newsletter on our website. Now we're going to analyze the recent hedge fund action surrounding Trillium Therapeutics Inc. (NASDAQ:TRIL).Do Hedge Funds Think TRIL Is A Good Stock To Buy Now?
在Insider Monkey，我們不遺餘力地尋找下一個偉大的投資點子。例如，眾議院通過了一項里程碑式的法案，將大麻合法化。所以，我們正在祕密調查這件事大麻庫存現在就來。我們看了一遍像15個人這樣的清單最值得買入的藍籌股挑選最好的大盤股進行買入。儘管我們只推薦了我們分析的公司中很小一部分的頭寸，但我們會盡可能多地查看股票。我們讀對衝基金投資者的信，聽對衝基金會議上的股票推介。您可以在我們的網站上訂閲我們的免費每日時事通訊。現在我們來分析一下最近對衝基金圍繞Trillium治療公司(納斯達克股票代碼：TRIL)採取的行動。對衝基金認為Tril是現在值得買入的股票嗎？
At Q3's end, a total of 32 of the hedge funds tracked by Insider Monkey were long this stock, a change of 28% from the previous quarter. On the other hand, there were a total of 4 hedge funds with a bullish position in TRIL a year ago. So, let's examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.
截至第三季度末，在Insider Monkey追蹤的對衝基金中，共有32只基金做多這隻股票，較上一季度變化了28%。另一方面，一年前TRIL共有4家對衝基金持有看漲頭寸。那麼，讓我們來看看哪些對衝基金是這隻股票的最大持有者之一，哪些對衝基金正在採取重大行動。
More specifically, RA Capital Management was the largest shareholder of Trillium Therapeutics Inc. (NASDAQ:TRIL), with a stake worth $87.6 million reported as of the end of September. Trailing RA Capital Management was Avoro Capital Advisors (venBio Select Advisor), which amassed a stake valued at $78.2 million. Citadel Investment Group, Frazier Healthcare Partners, and Cormorant Asset Management were also very fond of the stock, becoming one of the largest hedge fund holders of the company. In terms of the portfolio weights assigned to each position Ghost Tree Capital allocated the biggest weight to Trillium Therapeutics Inc. (NASDAQ:TRIL), around 8.01% of its 13F portfolio. Frazier Healthcare Partners is also relatively very bullish on the stock, designating 3.55 percent of its 13F equity portfolio to TRIL.
更具體地説，RA資本管理公司是Trillium治療公司(納斯達克市場代碼：TRIL)的最大股東，截至9月底的報告價值8760萬美元。緊隨其後的是Avoro Capital Advisors(VenBio Select Advisor)，它積累了價值7820萬美元的股份。Citadel Investment Group、Frazier Healthcare Partners和Cormorant Asset Management也非常喜歡這隻股票，成為一該公司最大的對衝基金持有者。就分配給每個職位的投資組合權重而言，Ghost Tree Capital分配給Trillium治療公司(納斯達克市場代碼：TRIL)的權重最大，約佔其13F投資組合的8.01%。Frazier Healthcare Partners也相對非常看好該股，將其13F股票投資組合中的3.55%指定為Tril。
As one would reasonably expect, key money managers were breaking ground themselves. Cormorant Asset Management, managed by Bihua Chen, initiated the biggest position in Trillium Therapeutics Inc. (NASDAQ:TRIL). Cormorant Asset Management had $35.5 million invested in the company at the end of the quarter. Richard Driehaus's Driehaus Capital also initiated a $12.8 million position during the quarter. The following funds were also among the new TRIL investors: Manfred Yu's Acuta Capital Partners, Benjamin A. Smith's Laurion Capital Management, and Matthew L Pinz's Pinz Capital.
正如人們可以合理預期的那樣，關鍵的基金經理們自己也在破土動工。由陳碧華(Bihua Chen)管理的Cormorant資產管理公司(Cormorant Asset Management)在延齡治療公司(納斯達克市場代碼：TRIL)設立了最大的頭寸。截至季度末，Cormorant Asset Management向該公司投資了3550萬美元。理查德·德里豪斯(Richard Driehaus)的德里豪斯資本(Driehaus Capital)也在本季度啟動了1280萬美元的頭寸。以下基金也在新的TRIL投資者之列：曼弗雷德·餘(Manfred Yu)的Acuta Capital Partners、本傑明·A·史密斯(Benjamin A.Smith)的Laurion Capital Management和馬修·L·品茨(Matthew L Pinz)的Pinz Capital。
Let's now review hedge fund activity in other stocks - not necessarily in the same industry as Trillium Therapeutics Inc. (NASDAQ:TRIL) but similarly valued. These stocks are First Merchants Corporation (NASDAQ:FRME), Alexander's, Inc. (NYSE:ALX), Seabridge Gold, Inc. (NYSE:SA), CBIZ, Inc. (NYSE:CBZ), ACM Research, Inc. (NASDAQ:ACMR), Columbia Property Trust Inc (NYSE:CXP), and Xperi Holding Corporation (NASDAQ:XPER). This group of stocks' market caps match TRIL's market cap.
現在讓我們回顧一下對衝基金在其他股票中的活動--不一定與Trillium Treateutics Inc.(納斯達克股票代碼：TRIL)在同一行業，但估值相似。這些股票是第一招商局(納斯達克市場代碼：FRME)，亞歷山大百貨公司。(紐約證券交易所代碼：ALX)，Seabbridge Gold，Inc.。(紐約證券交易所代碼：SA)，CBIZ，Inc.。(紐約證券交易所代碼：CBZ)，ACM研究公司(納斯達克股票代碼：ACMR)，哥倫比亞房地產信託公司(紐約證券交易所股票代碼：CXP)，以及Xperi控股公司(納斯達克股票代碼：XPER)這組股票的市值與Tril的市值相當。
[table] Ticker, No of HFs with positions, Total Value of HF Positions (x1000), Change in HF Position FRME,15,65819,4 ALX,10,99516,2 SA,10,68702,2 CBZ,14,182425,0 ACMR,16,129786,5 CXP,15,47691,-1 XPER,23,96085,1 Average,14.7,98575,1.9 [/table]
[表格]股票代碼，帶位置的HFs數量，HF位置的總值(X1000)，HF位置變化FRME，15,65819，4 ALX，10,99516，2 SA，10,68702，2 CBZ，14,182425，0 ACMR，16,129786，5 CxP，15,47691，-1 Xper，23,96085，1平均值，14.7,98575，1.9[/TABLE]
View table here if you experience formatting issues.
如果您遇到格式問題，請在此處查看錶格。
As you can see these stocks had an average of 14.7 hedge funds with bullish positions and the average amount invested in these stocks was $99 million. That figure was $465 million in TRIL's case. Xperi Holding Corporation (NASDAQ:XPER) is the most popular stock in this table. On the other hand Alexander's, Inc. (NYSE:ALX) is the least popular one with only 10 bullish hedge fund positions. Compared to these stocks Trillium Therapeutics Inc. (NASDAQ:TRIL) is more popular among hedge funds. Our overall hedge fund sentiment score for TRIL is 90. Stocks with higher number of hedge fund positions relative to other stocks as well as relative to their historical range receive a higher sentiment score. Our calculations showed that top 20 most popular stocks among hedge funds returned 41.3% in 2019 and outperformed the S&P 500 ETF (SPY) by 10 percentage points. These stocks gained 33.3% in 2020 through December 18th and still beat the market by 16.4 percentage points. Unfortunately TRIL wasn't nearly as popular as these 20 stocks and hedge funds that were betting on TRIL were disappointed as the stock returned -12% since the end of the third quarter (through 12/18) and underperformed the market. If you are interested in investing in large cap stocks with huge upside potential, you should check out the top 20 most popular stocks among hedge funds as most of these stocks already outperformed the market in 2020.
正如你所看到的，這些股票平均有14.7只持有看漲頭寸的對衝基金，平均投資於這些股票的金額為9900萬美元。在特里爾的案例中，這個數字是4.65億美元。Xperi Holding Corporation(納斯達克股票代碼：XPER)是本表中最受歡迎的股票。另一方面，亞歷山大公司(NYSE：ALX)是最不受歡迎的公司，只有10個看漲對衝基金頭寸。與這些股票相比，Trillium治療公司(納斯達克股票代碼：TRIL)在對衝基金中更受歡迎。我們對TRIL的整體對衝基金情緒評分為90分。與其他股票相比，對衝基金持倉數量較多的股票，以及相對於其歷史區間的股票，獲得更高的情緒得分。我們的計算顯示，對衝基金中最受歡迎的前20只股票在2019年的回報率為41.3%，表現比標準普爾500指數交易所交易基金(SPY)高出10個百分點。截至12月18日，這些股票在2020年上漲了33.3%，但仍比大盤高出16.4個百分點。不幸的是，TRIL遠不如這20只股票受歡迎，押注TRIL的對衝基金感到失望，因為該股自第三季度末(截至12月12日)的回報率為-12%，表現遜於大盤。如果你有興趣投資具有巨大上漲潛力的大盤股，你應該看看對衝基金中最受歡迎的20只股票，因為這些股票中的大多數在2020年已經跑贏了大盤。
Get real-time email alerts: Follow Trillium Therapeutics Inc. (NASDAQ:TRIL)
獲取實時電子郵件提醒：關注Trillium Treateutics Inc.(納斯達克股票代碼：TRIL)
Disclosure: None. This article was originally published at Insider Monkey.
披露：沒有。本文最初發表在“內幕猴子”(Insider Monkey)雜誌上。
Related ContentHow to Best Use Insider Monkey To Increase Your ReturnsTop 20 Richest People In The World12 Highest Paying Part Time Jobs for College Students
相關內容如何最好地利用內幕猴子來提高回報率世界上最富有的20人12名大學生收入最高的兼職工作
譯文內容由第三人軟體翻譯。